Stockreport

Oncternal Therapeutics Announces Increased Focus of the Cirmtuzumab ROR1 Antibody Program on Mantle Cell Lymphoma

Oncternal Therapeutics, Inc.  (ONCT) 
Last oncternal therapeutics, inc. earnings: 8/8 04:01 pm Check Earnings Report
PDF - Increasing planned enrollment of patients with MCL in ongoing CIRLL Phase 1/2 clinical trial of cirmtuzumab with ibrutinib based on encouraging data presented at ASCO [Read more]